Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Alphamab Oncology ( (HK:9966) ).
Alphamab Oncology announced a decision to repurchase up to HK$30 million worth of its own shares from the open market, as authorized by a mandate approved at their annual general meeting. This move is intended to reflect the company’s confidence in its business prospects and to potentially enhance shareholder value, while being financed through existing cash reserves. The repurchase plan is subject to market conditions and regulatory compliance, with no guarantee on the timing or quantity of shares to be repurchased.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$11.00 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
More about Alphamab Oncology
Alphamab Oncology is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative cancer therapies. The company operates in the oncology sector and is listed on the Hong Kong Stock Exchange.
Average Trading Volume: 3,856,566
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.6B
For an in-depth examination of 9966 stock, go to TipRanks’ Overview page.